PITTSBURGH, Oct. 23, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to Forbes' list of World's Best Employers 2023. Viatris has received this recognition in each of its first three years since forming in 2020. This recognition is presented by Forbes and Statista, the world-leading statistics portal and industry ranking provider.
"Being recognized again by Forbes as one of the World's Best Employers is a real testament to the commitment our colleagues have for our mission of empowering people worldwide to live healthier at every stage of life and to each other," said Andrew Enrietti, Chief Human Relations Officer, Viatris. "Everyone is deeply invested in making an impact together and it shows. Success takes all of us doing our part and I want to thank each and every one of our colleagues for all that they have done and continue to do to create the strong culture we have."
The World's Best Employers 2023 title is intended to reinforce companies that provide excellent employment opportunities at the local and international level. To determine the 2023 ranking, Statista surveyed 170,000 full-time and part-time workers from 55 countries working for multinational companies and institutions. The anonymous evaluations were based on direct and indirect recommendations from employees that were asked to rate their willingness to recommend their own employers to friends and family. Employee evaluations also included other employers in their respective industries that stood out either positively or negatively.
To learn more about Viatris' performance-driven, highly engaging and inclusive culture please visit its careers site. You can also learn more by reading its 2022 Sustainability Report, which outlines the company's 2022 achievements and progress across key areas including Access and Global Health, Our People, the Environment and the Community.
Being named to Forbes' List of the World's Best Employers 2023 follows inclusion on 3BL's 100 Best Corporate Citizens list. Additional accolades for Viatris include inclusion on Newsweek's America's Greenest Companies 2024, TIME's World's Best Companies 2023 list and USA Today's inaugural list of America's Climate Leaders 2023. The Company has also been included on Forbes' list of World's best Employers 2022, Fortune's Change the World list, Newsweek's America's Most Responsible Companies 2022 list, a Great Place to Work® certification in India, Capital Magazine's Best Employers in France list, and HR Asia's Best Companies to Work for in Asia (Taiwan), among others.
About Viatris
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life's moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter, LinkedIn, Instagram and YouTube.
Last Trade: | US$11.89 |
Daily Change: | 0.14 1.19 |
Daily Volume: | 2,441,506 |
Market Cap: | US$14.140B |
October 16, 2024 October 09, 2024 September 30, 2024 August 23, 2024 August 08, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB